nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—CYP2B6—Sorafenib—thyroid cancer	0.0923	0.133	CbGbCtD
Azelastine—CYP3A5—Sorafenib—thyroid cancer	0.0727	0.105	CbGbCtD
Azelastine—CYP2C8—Sorafenib—thyroid cancer	0.0699	0.101	CbGbCtD
Azelastine—CYP2C19—Sorafenib—thyroid cancer	0.0587	0.0847	CbGbCtD
Azelastine—CYP2B6—Doxorubicin—thyroid cancer	0.056	0.0808	CbGbCtD
Azelastine—CYP1A2—Sorafenib—thyroid cancer	0.0541	0.0781	CbGbCtD
Azelastine—CYP2C9—Sorafenib—thyroid cancer	0.0488	0.0704	CbGbCtD
Azelastine—ABCB1—Sorafenib—thyroid cancer	0.0473	0.0683	CbGbCtD
Azelastine—CYP3A4—Vandetanib—thyroid cancer	0.0471	0.0679	CbGbCtD
Azelastine—CYP2D6—Sorafenib—thyroid cancer	0.0446	0.0644	CbGbCtD
Azelastine—ABCB1—Doxorubicin—thyroid cancer	0.0287	0.0414	CbGbCtD
Azelastine—CYP3A4—Sorafenib—thyroid cancer	0.0284	0.0409	CbGbCtD
Azelastine—CYP2D6—Doxorubicin—thyroid cancer	0.0271	0.0391	CbGbCtD
Azelastine—CYP3A4—Doxorubicin—thyroid cancer	0.0172	0.0248	CbGbCtD
Azelastine—Mucosal inflammation—Sorafenib—thyroid cancer	0.00527	0.019	CcSEcCtD
Azelastine—Gastroenteritis—Vandetanib—thyroid cancer	0.00354	0.0127	CcSEcCtD
Azelastine—Atrial fibrillation—Vandetanib—thyroid cancer	0.00331	0.0119	CcSEcCtD
Azelastine—Glossitis—Sorafenib—thyroid cancer	0.00317	0.0114	CcSEcCtD
Azelastine—Influenza like illness—Sorafenib—thyroid cancer	0.00283	0.0102	CcSEcCtD
Azelastine—Nasopharyngitis—Vandetanib—thyroid cancer	0.00281	0.0101	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00277	0.00996	CcSEcCtD
Azelastine—Bronchospasm—Vandetanib—thyroid cancer	0.00267	0.0096	CcSEcCtD
Azelastine—Mouth ulceration—Sorafenib—thyroid cancer	0.00264	0.00949	CcSEcCtD
Azelastine—Bronchitis—Vandetanib—thyroid cancer	0.00261	0.00939	CcSEcCtD
Azelastine—Furunculosis—Epirubicin—thyroid cancer	0.00254	0.00913	CcSEcCtD
Azelastine—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00252	0.00907	CcSEcCtD
Azelastine—Pollakiuria—Vandetanib—thyroid cancer	0.00251	0.00902	CcSEcCtD
Azelastine—Dysaesthesia—Epirubicin—thyroid cancer	0.00249	0.00897	CcSEcCtD
Azelastine—Eczema—Sorafenib—thyroid cancer	0.00236	0.00848	CcSEcCtD
Azelastine—Conjunctivitis—Vandetanib—thyroid cancer	0.00235	0.00846	CcSEcCtD
Azelastine—Furunculosis—Doxorubicin—thyroid cancer	0.00235	0.00844	CcSEcCtD
Azelastine—Ulcerative stomatitis—Epirubicin—thyroid cancer	0.00234	0.0084	CcSEcCtD
Azelastine—Haematuria—Vandetanib—thyroid cancer	0.00231	0.0083	CcSEcCtD
Azelastine—Dysaesthesia—Doxorubicin—thyroid cancer	0.00231	0.0083	CcSEcCtD
Azelastine—Aphthous stomatitis—Epirubicin—thyroid cancer	0.0023	0.00827	CcSEcCtD
Azelastine—Epistaxis—Vandetanib—thyroid cancer	0.00228	0.00821	CcSEcCtD
Azelastine—Sinusitis—Vandetanib—thyroid cancer	0.00227	0.00817	CcSEcCtD
Azelastine—Furuncle—Epirubicin—thyroid cancer	0.0022	0.00791	CcSEcCtD
Azelastine—Ulcerative stomatitis—Doxorubicin—thyroid cancer	0.00216	0.00777	CcSEcCtD
Azelastine—Aphthous stomatitis—Doxorubicin—thyroid cancer	0.00213	0.00765	CcSEcCtD
Azelastine—Visual impairment—Vandetanib—thyroid cancer	0.00209	0.00753	CcSEcCtD
Azelastine—Furuncle—Doxorubicin—thyroid cancer	0.00203	0.00732	CcSEcCtD
Azelastine—Eye disorder—Vandetanib—thyroid cancer	0.00203	0.0073	CcSEcCtD
Azelastine—Mucosal inflammation—Epirubicin—thyroid cancer	0.00195	0.00701	CcSEcCtD
Azelastine—Nasopharyngitis—Sorafenib—thyroid cancer	0.00189	0.00681	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00187	0.00672	CcSEcCtD
Azelastine—Dysgeusia—Vandetanib—thyroid cancer	0.00185	0.00666	CcSEcCtD
Azelastine—Mucosal inflammation—Doxorubicin—thyroid cancer	0.0018	0.00648	CcSEcCtD
Azelastine—Vision blurred—Vandetanib—thyroid cancer	0.00178	0.00641	CcSEcCtD
Azelastine—Parosmia—Epirubicin—thyroid cancer	0.00166	0.00598	CcSEcCtD
Azelastine—Cough—Vandetanib—thyroid cancer	0.00165	0.00594	CcSEcCtD
Azelastine—Hypertension—Vandetanib—thyroid cancer	0.00163	0.00587	CcSEcCtD
Azelastine—Chest pain—Vandetanib—thyroid cancer	0.00161	0.00579	CcSEcCtD
Azelastine—Anxiety—Vandetanib—thyroid cancer	0.0016	0.00577	CcSEcCtD
Azelastine—Dry mouth—Vandetanib—thyroid cancer	0.00157	0.00566	CcSEcCtD
Azelastine—Epistaxis—Sorafenib—thyroid cancer	0.00154	0.00554	CcSEcCtD
Azelastine—Parosmia—Doxorubicin—thyroid cancer	0.00154	0.00553	CcSEcCtD
Azelastine—Infection—Vandetanib—thyroid cancer	0.00153	0.00552	CcSEcCtD
Azelastine—Laryngitis—Epirubicin—thyroid cancer	0.0015	0.00538	CcSEcCtD
Azelastine—Albuminuria—Epirubicin—thyroid cancer	0.00144	0.0052	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00141	0.00506	CcSEcCtD
Azelastine—Paraesthesia—Vandetanib—thyroid cancer	0.00139	0.00499	CcSEcCtD
Azelastine—Laryngitis—Doxorubicin—thyroid cancer	0.00138	0.00498	CcSEcCtD
Azelastine—Dyspnoea—Vandetanib—thyroid cancer	0.00138	0.00495	CcSEcCtD
Azelastine—Flushing—Sorafenib—thyroid cancer	0.00136	0.00489	CcSEcCtD
Azelastine—Albuminuria—Doxorubicin—thyroid cancer	0.00134	0.00481	CcSEcCtD
Azelastine—Stinging—Epirubicin—thyroid cancer	0.00133	0.00479	CcSEcCtD
Azelastine—Ageusia—Epirubicin—thyroid cancer	0.00133	0.00479	CcSEcCtD
Azelastine—Fatigue—Vandetanib—thyroid cancer	0.00133	0.00479	CcSEcCtD
Azelastine—Pain—Vandetanib—thyroid cancer	0.00132	0.00475	CcSEcCtD
Azelastine—Constipation—Vandetanib—thyroid cancer	0.00132	0.00475	CcSEcCtD
Azelastine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00126	0.00454	CcSEcCtD
Azelastine—Dysgeusia—Sorafenib—thyroid cancer	0.00125	0.00449	CcSEcCtD
Azelastine—Breast pain—Epirubicin—thyroid cancer	0.00124	0.00445	CcSEcCtD
Azelastine—Ageusia—Doxorubicin—thyroid cancer	0.00123	0.00443	CcSEcCtD
Azelastine—Stinging—Doxorubicin—thyroid cancer	0.00123	0.00443	CcSEcCtD
Azelastine—Amenorrhoea—Epirubicin—thyroid cancer	0.00123	0.00442	CcSEcCtD
Azelastine—Body temperature increased—Vandetanib—thyroid cancer	0.00122	0.00439	CcSEcCtD
Azelastine—Abdominal pain—Vandetanib—thyroid cancer	0.00122	0.00439	CcSEcCtD
Azelastine—Viral infection—Epirubicin—thyroid cancer	0.00119	0.00429	CcSEcCtD
Azelastine—Thinking abnormal—Epirubicin—thyroid cancer	0.00118	0.00424	CcSEcCtD
Azelastine—Lacrimation increased—Epirubicin—thyroid cancer	0.00117	0.00421	CcSEcCtD
Azelastine—Herpes simplex—Epirubicin—thyroid cancer	0.00117	0.00421	CcSEcCtD
Azelastine—Glossitis—Epirubicin—thyroid cancer	0.00117	0.00421	CcSEcCtD
Azelastine—Breast pain—Doxorubicin—thyroid cancer	0.00114	0.00411	CcSEcCtD
Azelastine—Ulcer—Epirubicin—thyroid cancer	0.00114	0.0041	CcSEcCtD
Azelastine—Amenorrhoea—Doxorubicin—thyroid cancer	0.00114	0.00409	CcSEcCtD
Azelastine—Cough—Sorafenib—thyroid cancer	0.00111	0.004	CcSEcCtD
Azelastine—Asthenia—Vandetanib—thyroid cancer	0.00111	0.00398	CcSEcCtD
Azelastine—Viral infection—Doxorubicin—thyroid cancer	0.0011	0.00397	CcSEcCtD
Azelastine—Hypertension—Sorafenib—thyroid cancer	0.0011	0.00396	CcSEcCtD
Azelastine—Pruritus—Vandetanib—thyroid cancer	0.00109	0.00393	CcSEcCtD
Azelastine—Thinking abnormal—Doxorubicin—thyroid cancer	0.00109	0.00392	CcSEcCtD
Azelastine—Myalgia—Sorafenib—thyroid cancer	0.00109	0.00391	CcSEcCtD
Azelastine—Herpes simplex—Doxorubicin—thyroid cancer	0.00108	0.00389	CcSEcCtD
Azelastine—Glossitis—Doxorubicin—thyroid cancer	0.00108	0.00389	CcSEcCtD
Azelastine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00108	0.00389	CcSEcCtD
Azelastine—Dermatitis contact—Epirubicin—thyroid cancer	0.00107	0.00383	CcSEcCtD
Azelastine—Dry mouth—Sorafenib—thyroid cancer	0.00106	0.00382	CcSEcCtD
Azelastine—Diarrhoea—Vandetanib—thyroid cancer	0.00106	0.0038	CcSEcCtD
Azelastine—Ulcer—Doxorubicin—thyroid cancer	0.00106	0.00379	CcSEcCtD
Azelastine—Influenza like illness—Epirubicin—thyroid cancer	0.00105	0.00377	CcSEcCtD
Azelastine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00104	0.00375	CcSEcCtD
Azelastine—Infection—Sorafenib—thyroid cancer	0.00103	0.00372	CcSEcCtD
Azelastine—Dizziness—Vandetanib—thyroid cancer	0.00102	0.00367	CcSEcCtD
Azelastine—Dermatitis contact—Doxorubicin—thyroid cancer	0.000986	0.00355	CcSEcCtD
Azelastine—Vomiting—Vandetanib—thyroid cancer	0.000981	0.00353	CcSEcCtD
Azelastine—Mouth ulceration—Epirubicin—thyroid cancer	0.000975	0.00351	CcSEcCtD
Azelastine—Rash—Vandetanib—thyroid cancer	0.000973	0.0035	CcSEcCtD
Azelastine—Dermatitis—Vandetanib—thyroid cancer	0.000972	0.0035	CcSEcCtD
Azelastine—Influenza like illness—Doxorubicin—thyroid cancer	0.000969	0.00349	CcSEcCtD
Azelastine—Headache—Vandetanib—thyroid cancer	0.000967	0.00348	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000949	0.00341	CcSEcCtD
Azelastine—Abnormal vision—Epirubicin—thyroid cancer	0.000941	0.00338	CcSEcCtD
Azelastine—Mental disability—Epirubicin—thyroid cancer	0.000936	0.00337	CcSEcCtD
Azelastine—Dyspnoea—Sorafenib—thyroid cancer	0.000928	0.00334	CcSEcCtD
Azelastine—Nausea—Vandetanib—thyroid cancer	0.000917	0.0033	CcSEcCtD
Azelastine—Mouth ulceration—Doxorubicin—thyroid cancer	0.000902	0.00325	CcSEcCtD
Azelastine—Fatigue—Sorafenib—thyroid cancer	0.000898	0.00323	CcSEcCtD
Azelastine—Pain—Sorafenib—thyroid cancer	0.00089	0.0032	CcSEcCtD
Azelastine—Constipation—Sorafenib—thyroid cancer	0.00089	0.0032	CcSEcCtD
Azelastine—Eczema—Epirubicin—thyroid cancer	0.000871	0.00313	CcSEcCtD
Azelastine—Abnormal vision—Doxorubicin—thyroid cancer	0.00087	0.00313	CcSEcCtD
Azelastine—Eye pain—Epirubicin—thyroid cancer	0.000867	0.00312	CcSEcCtD
Azelastine—Mental disability—Doxorubicin—thyroid cancer	0.000866	0.00311	CcSEcCtD
Azelastine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000851	0.00306	CcSEcCtD
Azelastine—Increased appetite—Epirubicin—thyroid cancer	0.000833	0.003	CcSEcCtD
Azelastine—Abdominal pain—Sorafenib—thyroid cancer	0.000823	0.00296	CcSEcCtD
Azelastine—Body temperature increased—Sorafenib—thyroid cancer	0.000823	0.00296	CcSEcCtD
Azelastine—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000809	0.00291	CcSEcCtD
Azelastine—Eczema—Doxorubicin—thyroid cancer	0.000806	0.0029	CcSEcCtD
Azelastine—Eye pain—Doxorubicin—thyroid cancer	0.000802	0.00289	CcSEcCtD
Azelastine—Increased appetite—Doxorubicin—thyroid cancer	0.000771	0.00277	CcSEcCtD
Azelastine—Hypersensitivity—Sorafenib—thyroid cancer	0.000767	0.00276	CcSEcCtD
Azelastine—Face oedema—Epirubicin—thyroid cancer	0.000756	0.00272	CcSEcCtD
Azelastine—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000748	0.00269	CcSEcCtD
Azelastine—Asthenia—Sorafenib—thyroid cancer	0.000747	0.00269	CcSEcCtD
Azelastine—Pruritus—Sorafenib—thyroid cancer	0.000737	0.00265	CcSEcCtD
Azelastine—Diarrhoea—Sorafenib—thyroid cancer	0.000712	0.00256	CcSEcCtD
Azelastine—Nasopharyngitis—Epirubicin—thyroid cancer	0.0007	0.00252	CcSEcCtD
Azelastine—Face oedema—Doxorubicin—thyroid cancer	0.000699	0.00252	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00069	0.00248	CcSEcCtD
Azelastine—Dizziness—Sorafenib—thyroid cancer	0.000688	0.00248	CcSEcCtD
Azelastine—Asthma—Epirubicin—thyroid cancer	0.000677	0.00243	CcSEcCtD
Azelastine—Vomiting—Sorafenib—thyroid cancer	0.000662	0.00238	CcSEcCtD
Azelastine—Rash—Sorafenib—thyroid cancer	0.000656	0.00236	CcSEcCtD
Azelastine—Dermatitis—Sorafenib—thyroid cancer	0.000656	0.00236	CcSEcCtD
Azelastine—Headache—Sorafenib—thyroid cancer	0.000652	0.00235	CcSEcCtD
Azelastine—Bronchitis—Epirubicin—thyroid cancer	0.000651	0.00234	CcSEcCtD
Azelastine—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000648	0.00233	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000639	0.0023	CcSEcCtD
Azelastine—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000629	0.00226	CcSEcCtD
Azelastine—Asthma—Doxorubicin—thyroid cancer	0.000626	0.00225	CcSEcCtD
Azelastine—Pollakiuria—Epirubicin—thyroid cancer	0.000625	0.00225	CcSEcCtD
Azelastine—Nausea—Sorafenib—thyroid cancer	0.000618	0.00222	CcSEcCtD
Azelastine—Weight increased—Epirubicin—thyroid cancer	0.000616	0.00221	CcSEcCtD
Azelastine—Bronchitis—Doxorubicin—thyroid cancer	0.000602	0.00217	CcSEcCtD
Azelastine—Conjunctivitis—Epirubicin—thyroid cancer	0.000586	0.00211	CcSEcCtD
Azelastine—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000582	0.00209	CcSEcCtD
Azelastine—Pollakiuria—Doxorubicin—thyroid cancer	0.000578	0.00208	CcSEcCtD
Azelastine—Haematuria—Epirubicin—thyroid cancer	0.000575	0.00207	CcSEcCtD
Azelastine—Weight increased—Doxorubicin—thyroid cancer	0.00057	0.00205	CcSEcCtD
Azelastine—Epistaxis—Epirubicin—thyroid cancer	0.000569	0.00205	CcSEcCtD
Azelastine—Sinusitis—Epirubicin—thyroid cancer	0.000566	0.00204	CcSEcCtD
Azelastine—Rhinitis—Epirubicin—thyroid cancer	0.000543	0.00195	CcSEcCtD
Azelastine—Conjunctivitis—Doxorubicin—thyroid cancer	0.000543	0.00195	CcSEcCtD
Azelastine—Hypoaesthesia—Epirubicin—thyroid cancer	0.000539	0.00194	CcSEcCtD
Azelastine—Pharyngitis—Epirubicin—thyroid cancer	0.000538	0.00193	CcSEcCtD
Azelastine—Haematuria—Doxorubicin—thyroid cancer	0.000532	0.00191	CcSEcCtD
Azelastine—Epistaxis—Doxorubicin—thyroid cancer	0.000527	0.00189	CcSEcCtD
Azelastine—Sinusitis—Doxorubicin—thyroid cancer	0.000524	0.00188	CcSEcCtD
Azelastine—Visual impairment—Epirubicin—thyroid cancer	0.000522	0.00188	CcSEcCtD
Azelastine—Eye disorder—Epirubicin—thyroid cancer	0.000506	0.00182	CcSEcCtD
Azelastine—Flushing—Epirubicin—thyroid cancer	0.000503	0.00181	CcSEcCtD
Azelastine—Rhinitis—Doxorubicin—thyroid cancer	0.000502	0.00181	CcSEcCtD
Azelastine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000499	0.00179	CcSEcCtD
Azelastine—Pharyngitis—Doxorubicin—thyroid cancer	0.000497	0.00179	CcSEcCtD
Azelastine—Visual impairment—Doxorubicin—thyroid cancer	0.000483	0.00174	CcSEcCtD
Azelastine—Eye disorder—Doxorubicin—thyroid cancer	0.000468	0.00168	CcSEcCtD
Azelastine—Flushing—Doxorubicin—thyroid cancer	0.000465	0.00167	CcSEcCtD
Azelastine—Tension—Epirubicin—thyroid cancer	0.000463	0.00166	CcSEcCtD
Azelastine—Dysgeusia—Epirubicin—thyroid cancer	0.000462	0.00166	CcSEcCtD
Azelastine—Nervousness—Epirubicin—thyroid cancer	0.000458	0.00165	CcSEcCtD
Azelastine—Back pain—Epirubicin—thyroid cancer	0.000456	0.00164	CcSEcCtD
Azelastine—Vision blurred—Epirubicin—thyroid cancer	0.000444	0.0016	CcSEcCtD
Azelastine—Ill-defined disorder—Epirubicin—thyroid cancer	0.000437	0.00157	CcSEcCtD
Azelastine—Agitation—Epirubicin—thyroid cancer	0.000433	0.00156	CcSEcCtD
Azelastine—Tension—Doxorubicin—thyroid cancer	0.000428	0.00154	CcSEcCtD
Azelastine—Dysgeusia—Doxorubicin—thyroid cancer	0.000427	0.00154	CcSEcCtD
Azelastine—Malaise—Epirubicin—thyroid cancer	0.000425	0.00153	CcSEcCtD
Azelastine—Nervousness—Doxorubicin—thyroid cancer	0.000424	0.00152	CcSEcCtD
Azelastine—Vertigo—Epirubicin—thyroid cancer	0.000424	0.00152	CcSEcCtD
Azelastine—Back pain—Doxorubicin—thyroid cancer	0.000422	0.00152	CcSEcCtD
Azelastine—Palpitations—Epirubicin—thyroid cancer	0.000417	0.0015	CcSEcCtD
Azelastine—Cough—Epirubicin—thyroid cancer	0.000411	0.00148	CcSEcCtD
Azelastine—Vision blurred—Doxorubicin—thyroid cancer	0.000411	0.00148	CcSEcCtD
Azelastine—Hypertension—Epirubicin—thyroid cancer	0.000407	0.00146	CcSEcCtD
Azelastine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000405	0.00146	CcSEcCtD
Azelastine—Myalgia—Epirubicin—thyroid cancer	0.000401	0.00144	CcSEcCtD
Azelastine—Chest pain—Epirubicin—thyroid cancer	0.000401	0.00144	CcSEcCtD
Azelastine—Agitation—Doxorubicin—thyroid cancer	0.000401	0.00144	CcSEcCtD
Azelastine—Anxiety—Epirubicin—thyroid cancer	0.0004	0.00144	CcSEcCtD
Azelastine—Discomfort—Epirubicin—thyroid cancer	0.000397	0.00143	CcSEcCtD
Azelastine—Malaise—Doxorubicin—thyroid cancer	0.000393	0.00142	CcSEcCtD
Azelastine—Dry mouth—Epirubicin—thyroid cancer	0.000393	0.00141	CcSEcCtD
Azelastine—Vertigo—Doxorubicin—thyroid cancer	0.000392	0.00141	CcSEcCtD
Azelastine—Confusional state—Epirubicin—thyroid cancer	0.000388	0.0014	CcSEcCtD
Azelastine—Palpitations—Doxorubicin—thyroid cancer	0.000386	0.00139	CcSEcCtD
Azelastine—Anaphylactic shock—Epirubicin—thyroid cancer	0.000385	0.00138	CcSEcCtD
Azelastine—Infection—Epirubicin—thyroid cancer	0.000382	0.00137	CcSEcCtD
Azelastine—Cough—Doxorubicin—thyroid cancer	0.000381	0.00137	CcSEcCtD
Azelastine—Hypertension—Doxorubicin—thyroid cancer	0.000377	0.00135	CcSEcCtD
Azelastine—Tachycardia—Epirubicin—thyroid cancer	0.000376	0.00135	CcSEcCtD
Azelastine—Myalgia—Doxorubicin—thyroid cancer	0.000371	0.00134	CcSEcCtD
Azelastine—Chest pain—Doxorubicin—thyroid cancer	0.000371	0.00134	CcSEcCtD
Azelastine—Anxiety—Doxorubicin—thyroid cancer	0.00037	0.00133	CcSEcCtD
Azelastine—Discomfort—Doxorubicin—thyroid cancer	0.000367	0.00132	CcSEcCtD
Azelastine—Dry mouth—Doxorubicin—thyroid cancer	0.000363	0.00131	CcSEcCtD
Azelastine—Confusional state—Doxorubicin—thyroid cancer	0.000359	0.00129	CcSEcCtD
Azelastine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000356	0.00128	CcSEcCtD
Azelastine—Infection—Doxorubicin—thyroid cancer	0.000354	0.00127	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000351	0.00126	CcSEcCtD
Azelastine—Tachycardia—Doxorubicin—thyroid cancer	0.000347	0.00125	CcSEcCtD
Azelastine—Paraesthesia—Epirubicin—thyroid cancer	0.000346	0.00124	CcSEcCtD
Azelastine—Dyspnoea—Epirubicin—thyroid cancer	0.000343	0.00123	CcSEcCtD
Azelastine—Somnolence—Epirubicin—thyroid cancer	0.000342	0.00123	CcSEcCtD
Azelastine—Fatigue—Epirubicin—thyroid cancer	0.000332	0.00119	CcSEcCtD
Azelastine—Pain—Epirubicin—thyroid cancer	0.000329	0.00118	CcSEcCtD
Azelastine—Constipation—Epirubicin—thyroid cancer	0.000329	0.00118	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000324	0.00117	CcSEcCtD
Azelastine—Paraesthesia—Doxorubicin—thyroid cancer	0.00032	0.00115	CcSEcCtD
Azelastine—Dyspnoea—Doxorubicin—thyroid cancer	0.000317	0.00114	CcSEcCtD
Azelastine—Feeling abnormal—Epirubicin—thyroid cancer	0.000317	0.00114	CcSEcCtD
Azelastine—Somnolence—Doxorubicin—thyroid cancer	0.000317	0.00114	CcSEcCtD
Azelastine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000315	0.00113	CcSEcCtD
Azelastine—Fatigue—Doxorubicin—thyroid cancer	0.000307	0.0011	CcSEcCtD
Azelastine—Constipation—Doxorubicin—thyroid cancer	0.000304	0.0011	CcSEcCtD
Azelastine—Pain—Doxorubicin—thyroid cancer	0.000304	0.0011	CcSEcCtD
Azelastine—Abdominal pain—Epirubicin—thyroid cancer	0.000304	0.00109	CcSEcCtD
Azelastine—Body temperature increased—Epirubicin—thyroid cancer	0.000304	0.00109	CcSEcCtD
Azelastine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000293	0.00106	CcSEcCtD
Azelastine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000291	0.00105	CcSEcCtD
Azelastine—Hypersensitivity—Epirubicin—thyroid cancer	0.000283	0.00102	CcSEcCtD
Azelastine—Abdominal pain—Doxorubicin—thyroid cancer	0.000281	0.00101	CcSEcCtD
Azelastine—Body temperature increased—Doxorubicin—thyroid cancer	0.000281	0.00101	CcSEcCtD
Azelastine—Asthenia—Epirubicin—thyroid cancer	0.000276	0.000993	CcSEcCtD
Azelastine—Pruritus—Epirubicin—thyroid cancer	0.000272	0.000979	CcSEcCtD
Azelastine—Diarrhoea—Epirubicin—thyroid cancer	0.000263	0.000947	CcSEcCtD
Azelastine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000262	0.000944	CcSEcCtD
Azelastine—Asthenia—Doxorubicin—thyroid cancer	0.000255	0.000919	CcSEcCtD
Azelastine—Dizziness—Epirubicin—thyroid cancer	0.000254	0.000915	CcSEcCtD
Azelastine—Pruritus—Doxorubicin—thyroid cancer	0.000252	0.000906	CcSEcCtD
Azelastine—Vomiting—Epirubicin—thyroid cancer	0.000245	0.00088	CcSEcCtD
Azelastine—Diarrhoea—Doxorubicin—thyroid cancer	0.000244	0.000876	CcSEcCtD
Azelastine—Rash—Epirubicin—thyroid cancer	0.000243	0.000873	CcSEcCtD
Azelastine—Dermatitis—Epirubicin—thyroid cancer	0.000242	0.000872	CcSEcCtD
Azelastine—Headache—Epirubicin—thyroid cancer	0.000241	0.000867	CcSEcCtD
Azelastine—Dizziness—Doxorubicin—thyroid cancer	0.000235	0.000847	CcSEcCtD
Azelastine—Nausea—Epirubicin—thyroid cancer	0.000229	0.000822	CcSEcCtD
Azelastine—Vomiting—Doxorubicin—thyroid cancer	0.000226	0.000814	CcSEcCtD
Azelastine—Rash—Doxorubicin—thyroid cancer	0.000224	0.000807	CcSEcCtD
Azelastine—Dermatitis—Doxorubicin—thyroid cancer	0.000224	0.000807	CcSEcCtD
Azelastine—Headache—Doxorubicin—thyroid cancer	0.000223	0.000802	CcSEcCtD
Azelastine—Nausea—Doxorubicin—thyroid cancer	0.000211	0.000761	CcSEcCtD
Azelastine—HRH1—Signaling Pathways—TRIM33—thyroid cancer	4.07e-05	0.00141	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—CHST14—thyroid cancer	4.05e-05	0.0014	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—MINPP1—thyroid cancer	4.05e-05	0.0014	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—NDUFA13—thyroid cancer	3.95e-05	0.00137	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—MINPP1—thyroid cancer	3.82e-05	0.00132	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—MINPP1—thyroid cancer	3.78e-05	0.00131	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—TSHR—thyroid cancer	3.72e-05	0.00129	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—CHST14—thyroid cancer	3.72e-05	0.00129	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—TSHR—thyroid cancer	3.71e-05	0.00128	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PRKAR1A—thyroid cancer	3.66e-05	0.00127	CbGpPWpGaD
Azelastine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	3.57e-05	0.00124	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—HPGD—thyroid cancer	3.54e-05	0.00123	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—NDUFA13—thyroid cancer	3.53e-05	0.00122	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—HPGD—thyroid cancer	3.47e-05	0.0012	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—HPGD—thyroid cancer	3.46e-05	0.0012	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—NDUFA13—thyroid cancer	3.44e-05	0.00119	CbGpPWpGaD
Azelastine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	3.4e-05	0.00118	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—TSHR—thyroid cancer	3.36e-05	0.00117	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—CHST14—thyroid cancer	3.32e-05	0.00115	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PRKAR1A—thyroid cancer	3.31e-05	0.00115	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—NRG1—thyroid cancer	3.27e-05	0.00113	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—HPGD—thyroid cancer	3.27e-05	0.00113	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—NDUFA13—thyroid cancer	3.24e-05	0.00112	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—CHST14—thyroid cancer	3.24e-05	0.00112	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—MINPP1—thyroid cancer	3.23e-05	0.00112	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—NDUFA13—thyroid cancer	3.22e-05	0.00111	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	3.2e-05	0.00111	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	3.2e-05	0.00111	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—SST—thyroid cancer	3.18e-05	0.0011	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PTCH1—thyroid cancer	3.16e-05	0.00109	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.15e-05	0.00109	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	3.12e-05	0.00108	CbGpPWpGaD
Azelastine—KCNH2—Neuronal System—HRAS—thyroid cancer	3.1e-05	0.00108	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—CALCA—thyroid cancer	3.06e-05	0.00106	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—CHST14—thyroid cancer	3.05e-05	0.00106	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—CHST14—thyroid cancer	3.02e-05	0.00105	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TCF7L1—thyroid cancer	3e-05	0.00104	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—HPGD—thyroid cancer	3e-05	0.00104	CbGpPWpGaD
Azelastine—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	2.96e-05	0.00103	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TERT—thyroid cancer	2.94e-05	0.00102	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—SST—thyroid cancer	2.89e-05	0.001	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—SST—thyroid cancer	2.88e-05	0.000998	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PTCH1—thyroid cancer	2.86e-05	0.000991	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	2.83e-05	0.000979	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—HIF1A—thyroid cancer	2.81e-05	0.000973	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CALCA—thyroid cancer	2.78e-05	0.000964	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—CALCA—thyroid cancer	2.77e-05	0.000961	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—NDUFA13—thyroid cancer	2.75e-05	0.000952	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TCF7L1—thyroid cancer	2.72e-05	0.000941	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	2.69e-05	0.000931	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—HPGD—thyroid cancer	2.67e-05	0.000926	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.65e-05	0.000918	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—SST—thyroid cancer	2.62e-05	0.000906	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—HPGD—thyroid cancer	2.61e-05	0.000904	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CHST14—thyroid cancer	2.58e-05	0.000895	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CALCA—thyroid cancer	2.52e-05	0.000873	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—CDK1—thyroid cancer	2.52e-05	0.000872	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—TPR—thyroid cancer	2.52e-05	0.000872	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	2.52e-05	0.000872	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—MINPP1—thyroid cancer	2.49e-05	0.000864	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	2.48e-05	0.000858	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—NRAS—thyroid cancer	2.48e-05	0.000858	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—HPGD—thyroid cancer	2.46e-05	0.000852	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—HPGD—thyroid cancer	2.44e-05	0.000844	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	2.43e-05	0.000843	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.43e-05	0.000842	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.4e-05	0.00083	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—BRAF—thyroid cancer	2.33e-05	0.000806	CbGpPWpGaD
Azelastine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.28e-05	0.000791	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—CDK1—thyroid cancer	2.28e-05	0.00079	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.27e-05	0.000788	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TSHR—thyroid cancer	2.2e-05	0.000761	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.2e-05	0.000761	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.17e-05	0.000751	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PRKAR1A—thyroid cancer	2.16e-05	0.000748	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—KRAS—thyroid cancer	2.13e-05	0.000738	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.12e-05	0.000735	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—HPGD—thyroid cancer	2.08e-05	0.000722	CbGpPWpGaD
Azelastine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	2.07e-05	0.000716	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MEN1—thyroid cancer	2.06e-05	0.000715	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—TPR—thyroid cancer	2.03e-05	0.000704	CbGpPWpGaD
Azelastine—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.01e-05	0.000697	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PRKAR1A—thyroid cancer	2e-05	0.000692	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CHST14—thyroid cancer	1.99e-05	0.000691	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—TPR—thyroid cancer	1.99e-05	0.000689	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TSHR—thyroid cancer	1.99e-05	0.000689	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—TPR—thyroid cancer	1.99e-05	0.000688	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.98e-05	0.000685	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PRKAR1A—thyroid cancer	1.96e-05	0.000678	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PRKAR1A—thyroid cancer	1.96e-05	0.000677	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	1.95e-05	0.000677	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—SLC5A5—thyroid cancer	1.89e-05	0.000653	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—TPR—thyroid cancer	1.88e-05	0.00065	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MEN1—thyroid cancer	1.87e-05	0.000647	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTCH1—thyroid cancer	1.87e-05	0.000647	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	1.85e-05	0.000639	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—HRAS—thyroid cancer	1.81e-05	0.000627	CbGpPWpGaD
Azelastine—HRH3—GPCR downstream signaling—AKT1—thyroid cancer	1.76e-05	0.00061	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—TPR—thyroid cancer	1.72e-05	0.000596	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—SST—thyroid cancer	1.71e-05	0.000592	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—CCND1—thyroid cancer	1.7e-05	0.000588	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	1.69e-05	0.000586	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTCH1—thyroid cancer	1.69e-05	0.000585	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.69e-05	0.000585	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	1.69e-05	0.000584	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.67e-05	0.00058	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CALCA—thyroid cancer	1.64e-05	0.000569	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—PTEN—thyroid cancer	1.64e-05	0.000568	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—HPGD—thyroid cancer	1.61e-05	0.000557	CbGpPWpGaD
Azelastine—HRH3—Signaling by GPCR—AKT1—thyroid cancer	1.6e-05	0.000554	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—RXRA—thyroid cancer	1.58e-05	0.000549	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—SST—thyroid cancer	1.55e-05	0.000535	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—TPR—thyroid cancer	1.54e-05	0.000532	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.53e-05	0.000531	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—SLC5A5—thyroid cancer	1.52e-05	0.000527	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	1.51e-05	0.000523	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—TPR—thyroid cancer	1.5e-05	0.000519	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.5e-05	0.000519	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—SLC5A5—thyroid cancer	1.49e-05	0.000516	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CALCA—thyroid cancer	1.49e-05	0.000515	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDK1—thyroid cancer	1.49e-05	0.000515	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.49e-05	0.000515	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.47e-05	0.000511	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—NRAS—thyroid cancer	1.46e-05	0.000507	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—TPR—thyroid cancer	1.41e-05	0.000489	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.4e-05	0.000487	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—TPR—thyroid cancer	1.4e-05	0.000485	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.39e-05	0.000481	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.38e-05	0.000477	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.37e-05	0.000474	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDK1—thyroid cancer	1.35e-05	0.000467	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.32e-05	0.000456	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.29e-05	0.000446	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—RXRA—thyroid cancer	1.28e-05	0.000443	CbGpPWpGaD
Azelastine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.27e-05	0.000438	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—KRAS—thyroid cancer	1.26e-05	0.000436	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—RXRA—thyroid cancer	1.25e-05	0.000434	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—RXRA—thyroid cancer	1.25e-05	0.000433	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.25e-05	0.000432	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.21e-05	0.000418	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—TPR—thyroid cancer	1.2e-05	0.000414	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRG1—thyroid cancer	1.19e-05	0.000414	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—RXRA—thyroid cancer	1.18e-05	0.000409	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.18e-05	0.000408	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.15e-05	0.000398	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.15e-05	0.000398	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.12e-05	0.000389	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—TP53—thyroid cancer	1.12e-05	0.000388	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—RXRA—thyroid cancer	1.08e-05	0.000375	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRG1—thyroid cancer	1.08e-05	0.000374	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.08e-05	0.000373	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TERT—thyroid cancer	1.07e-05	0.000371	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—HRAS—thyroid cancer	1.07e-05	0.000371	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.07e-05	0.00037	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.06e-05	0.000366	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.05e-05	0.000365	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.05e-05	0.000363	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HIF1A—thyroid cancer	1.03e-05	0.000355	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PPARG—thyroid cancer	1e-05	0.000346	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	9.82e-06	0.00034	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TERT—thyroid cancer	9.71e-06	0.000336	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—RXRA—thyroid cancer	9.66e-06	0.000335	CbGpPWpGaD
Azelastine—HRH3—Signaling Pathways—AKT1—thyroid cancer	9.45e-06	0.000327	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—RXRA—thyroid cancer	9.43e-06	0.000327	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.39e-06	0.000325	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HIF1A—thyroid cancer	9.28e-06	0.000322	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—TPR—thyroid cancer	9.23e-06	0.00032	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	9.08e-06	0.000315	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—NRAS—thyroid cancer	9.04e-06	0.000313	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SLC5A5—thyroid cancer	8.96e-06	0.00031	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—RXRA—thyroid cancer	8.88e-06	0.000308	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—RXRA—thyroid cancer	8.81e-06	0.000305	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	8.56e-06	0.000297	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—BRAF—thyroid cancer	8.49e-06	0.000294	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.39e-06	0.000291	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—NRAS—thyroid cancer	8.18e-06	0.000283	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—thyroid cancer	8.07e-06	0.00028	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—thyroid cancer	7.9e-06	0.000274	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—thyroid cancer	7.89e-06	0.000273	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—thyroid cancer	7.87e-06	0.000273	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—thyroid cancer	7.78e-06	0.000269	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BRAF—thyroid cancer	7.69e-06	0.000266	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—RXRA—thyroid cancer	7.52e-06	0.000261	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—thyroid cancer	7.45e-06	0.000258	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.32e-06	0.000254	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—thyroid cancer	7.04e-06	0.000244	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	6.91e-06	0.000239	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—thyroid cancer	6.86e-06	0.000238	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—thyroid cancer	6.83e-06	0.000237	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—thyroid cancer	6.61e-06	0.000229	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—thyroid cancer	6.43e-06	0.000223	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—thyroid cancer	6.35e-06	0.00022	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—thyroid cancer	6.22e-06	0.000215	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—thyroid cancer	6.2e-06	0.000215	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—thyroid cancer	6.2e-06	0.000215	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—thyroid cancer	6.1e-06	0.000211	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—thyroid cancer	5.98e-06	0.000207	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—thyroid cancer	5.98e-06	0.000207	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—thyroid cancer	5.95e-06	0.000206	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—thyroid cancer	5.86e-06	0.000203	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—thyroid cancer	5.84e-06	0.000202	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—thyroid cancer	5.82e-06	0.000202	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—RXRA—thyroid cancer	5.81e-06	0.000201	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—thyroid cancer	5.61e-06	0.000194	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—thyroid cancer	5.61e-06	0.000194	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—thyroid cancer	5.56e-06	0.000193	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—thyroid cancer	5.54e-06	0.000192	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—thyroid cancer	5.42e-06	0.000188	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—thyroid cancer	5.42e-06	0.000188	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—thyroid cancer	5.41e-06	0.000187	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—thyroid cancer	5.37e-06	0.000186	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRAS—thyroid cancer	5.34e-06	0.000185	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—thyroid cancer	5.28e-06	0.000183	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—thyroid cancer	5.11e-06	0.000177	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRAS—thyroid cancer	4.83e-06	0.000167	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—thyroid cancer	4.8e-06	0.000166	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—thyroid cancer	4.75e-06	0.000165	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—thyroid cancer	4.69e-06	0.000162	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—thyroid cancer	4.68e-06	0.000162	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—thyroid cancer	4.59e-06	0.000159	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—thyroid cancer	4.41e-06	0.000153	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—thyroid cancer	4.37e-06	0.000152	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—thyroid cancer	4.18e-06	0.000145	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—thyroid cancer	4.16e-06	0.000144	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—thyroid cancer	4.08e-06	0.000141	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—thyroid cancer	4.08e-06	0.000141	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—thyroid cancer	3.95e-06	0.000137	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—thyroid cancer	3.9e-06	0.000135	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—thyroid cancer	3.85e-06	0.000133	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—thyroid cancer	3.81e-06	0.000132	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—thyroid cancer	3.74e-06	0.000129	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—thyroid cancer	3.7e-06	0.000128	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—thyroid cancer	3.67e-06	0.000127	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—thyroid cancer	3.53e-06	0.000122	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—thyroid cancer	3.45e-06	0.000119	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—thyroid cancer	3.26e-06	0.000113	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—thyroid cancer	3.19e-06	0.000111	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—thyroid cancer	3.12e-06	0.000108	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—thyroid cancer	3.12e-06	0.000108	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—thyroid cancer	3.12e-06	0.000108	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—thyroid cancer	2.95e-06	0.000102	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.88e-06	9.99e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—thyroid cancer	2.7e-06	9.36e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—thyroid cancer	2.52e-06	8.71e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—thyroid cancer	2.41e-06	8.35e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—thyroid cancer	2.35e-06	8.15e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—thyroid cancer	2.22e-06	7.68e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—thyroid cancer	2.2e-06	7.61e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—thyroid cancer	1.88e-06	6.51e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—thyroid cancer	1.45e-06	5.02e-05	CbGpPWpGaD
